Navigation Links
Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
Date:5/13/2009

LAIYANG, China, May 13 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc., (OTC Bulletin Board: JGBO; "Jiangbo" or the "Company") (which recently changed its name from Genesis Pharmaceuticals Enterprises, Inc., OTC Bulletin Board: GNPH), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that the Company will host a conference call at 9:30 a.m. Eastern on Tuesday, May 19, 2009 to discuss financial results for the third quarter ended March 31, 2009 of its fiscal year 2009.

Conference Call

The conference call will include Mr. Wubo Cao, Chairman and CEO, Mr. Haibo Xu, COO, and Ms. Elsa Sung, CFO, of Jiangbo Pharmaceuticals.

To participate in this live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: (888) 481-7939. International callers should call (617) 847-8707. The Conference Passcode is 564 145 01.

If you are unable to participate in the call at that time, replay of the conference call will be available from Tuesday, May 19, 2009 at 11:30 a.m. Eastern for fourteen days. To access the replay, call (888) 286-8010. International callers should call (617) 801-6888. The Conference Replay Passcode is 547 268 69.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, and electuary (sticky syrup) form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Company Contact:
     Ms. Elsa Sung, CFO
     Jiangbo Pharmaceuticals, Inc.
     Email: elsasung@jiangbo.com
     Tel   +1-954-727-8435
     Web:  http://www.jiangbopharma.com/

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Email: crocker.coulson@ccgir.com
     Tel:   +1-646-213-1915 (NY office)
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE Jiangbo Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
2. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
3. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
9. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
10. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
11. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... ... February 26, 2017 , ... NuevaCare, a leading home care agency based ... and Palo Alto, is proud to announce an important upgrade to its geographic information ... home care close to home, and by having city-specific pages, NuevaCare is answering that ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... staffing, scheduling, and reporting for healthcare organizations. This comprehensive and customizable solution ... staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure is ... specific LRRK2 mutation, according to a study released today at the 1st Pan ... a link between pesticides and incidence of sporadic PD through occupational exposure. This ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... tooth replacement options at his office, Antoine Dental Center. Currently, patients can get ... Some restrictions may apply, but patients can learn more about these offers by ...
(Date:2/24/2017)... ... 24, 2017 , ... An in-depth computational analysis of genetic variants implicated in ... eight genes that may explain why susceptibility to one of the disorders could place ... published today in the journal npj Schizophrenia. , “There is a wealth of ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... Period October – December 2016 ... to SEK -16.4 (-6.4) million Result after tax amounted to ... after dilution Cash flow from operating activities amounted to SEK ... Period full ... Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... Mass. , Feb. 24, 2017  Today, ... US dental labs have a new path to ... using the Biodenta implant library integrated into exocad ... must implement FDA compliant Good Manufacturing Processes (GMP,s) ... manufacturer with Biodenta, and complete an audit process. Then, ...
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
Breaking Medicine Technology: